Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02879617 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
A Phase 2 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT02879617 is a Phase 2 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Academic Thoracic Oncology Medical Investigators Consortium. The registered enrollment target is 47 participants, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02879617, a Phase 2 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Academic Thoracic Oncology Medical Investigators Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
Conditions Studied
Interventions
- DRUG durvalumab
Study Locations (2)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- Simmons Comprehensive Cancer Center - UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2022-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02879617
The ClinicalTrials.gov registry entry for NCT02879617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (84% lower). The listed sponsor is Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which durvalumab is the first listed.
NCT02879617 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT02879617 about?
NCT02879617 is a clinical study titled "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients". This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
What is the current status of trial NCT02879617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2017-04-04. Estimated completion is 2022-06-04.
What conditions does trial NCT02879617 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT02879617?
The interventions under investigation include: durvalumab (DRUG).
Who is sponsoring clinical trial NCT02879617?
This trial is sponsored by Academic Thoracic Oncology Medical Investigators Consortium, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02879617 being conducted?
This trial has 2 study locations across Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
RECRUITING · Phase 2
-
Pembrolizumab for Advanced NSCLC and PS 2-3
RECRUITING · Phase 2
-
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
ACTIVE NOT RECRUITING · Phase 2
-
PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung
ACTIVE NOT RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.